Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Psychiatric Disorders Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

NCT02953639
View directory record Official record
Conditions
Schizophrenia
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Galantamine for Cognition in People With Schizophrenia

NCT00320736
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Sep 23, 2026, 8:27 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation

NCT05112432
View directory record Official record
Conditions
Psychosis
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Duluth, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 23, 2026, 8:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality

NCT01212081
View directory record Official record
Conditions
Cannabis Use
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 23, 2026, 8:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional

CAFE Comparison of Atypicals in First Episode of Psychosis

NCT00034892
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions
Olanzapine, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 23, 2026, 8:27 AM EDT
Not listed No phase listed Observational

Assessment of Schizophrenia Patients' Clinical Study Experiences

NCT05948111
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

NCT00254202
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone, Ziprasidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765
View directory record Official record
Conditions
Schizophrenia
Interventions
AL-108, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 23, 2026, 8:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Appeal and Impact of E-cigarettes in Smokers With SMI

NCT03050853
View directory record Official record
Conditions
Tobacco Dependence, Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
E-cigarette
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Louisville, Kentucky • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

NCT00789698
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Lurasidone HC1, Quetiapine XR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

SimpleC Wellness Platform With Social Robot Interaction

NCT05296239
View directory record Official record
Conditions
Engagement, Patient, Mood, Quality of Life, Aging, Mild Cognitive Impairment, Cognitive Impairment, Dementia
Interventions
SimpleC Wellness Platform with Social Robot Interaction
Other
Lead sponsor
SimpleC, LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Athens, Georgia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 8:27 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation

NCT00801567
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Healthy Controls
Interventions
Magnetic resonance spectroscopy (MRS)
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

NCT00338598
View directory record Official record
Conditions
Alcoholism, Schizophrenia
Interventions
Glycine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 23, 2026, 8:27 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Teen Connection Project for Trans and Gender Minority Youth

NCT06587139
View directory record Official record
Conditions
Recreational Drug Use, Sexual Violence, Victimisation, Depressive Symptoms, Anxiety, Suicidal Ideation, Risk-Taking, Alcohol Drinking
Interventions
Teen Connection Project (TCP)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 23, 2026, 8:27 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Cardio Risk of Acute Schizophrenia Olanzapine Duke

NCT00672464
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Metformin, Simvastatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

NCT00616798
View directory record Official record
Conditions
Schizophrenia
Interventions
RO4917838, Placebo, Standard antipsychotic therapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First In Human Study Of PF-00184562 In Healthy Volunteers

NCT00150215
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-00184562, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone.

NCT05179525
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 23, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

NCT00351936
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 23, 2026, 8:27 AM EDT